聚乙二醇干扰素联合利巴韦林治疗HCV 6型感染者的临床疗效回顾性观察研究

发布时间：2018-04-23 23:16

本文选题：聚乙二醇干扰素 + 利巴韦林　；参考：《第三军医大学学报》2015年12期

【摘要】：目的探讨HCV 6型感染者的临床治疗方法。方法以聚乙二醇干扰素联合利巴韦林治疗HCV 6型感染者为试验组,治疗2/3型感染者为对照组,纳入病例必须完成治疗24周且随访时间达到24周以上。分析2组基本资料特征,比较2组病毒学应答效果。结果纳入HCV 6型感染者53例、2/3型感染者84例。HCV 6型、2/3型感染者获得RVR比例分别是88.7%、89.3%,率差95%可信区间为:(-0.113 9,0.101 9);获得EVR的比例分别是94.3%、96.4%,率差95%可信区间为:(-0.095 0,0.053 0);获得SVR的比例分别是86.8%、90.5%,率差95%可信区间为:(-0.147 6,0.073 6);HCV 6型、2/3型感染者RVR对SVR的阳性预测值分别为89.4%、93.3%,率差95%可信区间为:(-0.143 6,0.065 6);EVR对SVR的阳性预测值分别为88.0%、91.4%,率差95%可信区间为:(-0.142 8,0.074 8)。结论采用聚乙二醇干扰素联合利巴韦林治疗HCV 6型感染者的疗效非劣于2/3型感染者,故HCV 6型感染者推荐使用24周的标准联合抗病毒治疗方案。
[Abstract]:Objective to investigate the clinical treatment of HCV 6 infection. Methods PEG-interferon combined with ribavirin was used as experimental group and 2 / 3 infection group as control group. The included patients had to complete the treatment for 24 weeks and follow up for more than 24 weeks. The characteristics of basic data of two groups were analyzed and the virological response effects of two groups were compared. Results among the 53 cases of HCV 6 type 6 infection, 84 cases. HCV6 / 2 / 3 infection rate was 88.789. 3%, 95% confidence interval of 95% difference was 0: 0.113 9 + 0.101 9%, the proportion of EVR was 94.3% and 96.4%, the rate of 95% confidence interval was: 1% -0.095 0% 0.053%, and the difference between 95% and 95% was:% -0.095 0% 0.053%, and the difference was 95% (95%) and 95% (95%) respectively, and the difference was 95% (95%), and the difference was 95% (95%). The proportion of SVR was 86.80.The 95% confidence interval of the difference was -0.147 60.073.The positive predictive value of RVR to SVR was 89.40.143%, and the 95% confidence interval of 95% confidence interval was: -0.143 60.065 6EVR positive predictive value of SVR was 88.00.94%, and 95% confidence interval of RVR was: -0.142% 0.074.The positive predictive value of SVR was 88.00.142.The positive predictive value of SVR was 91.4%, and the difference was 95% between 0.142% and 0.074%, respectively. Conclusion the efficacy of pegylated interferon combined with ribavirin in the treatment of HCV 6 infection is not inferior to that of 2 / 3 infection, so the standard combined antiviral therapy for 24 weeks is recommended for HCV 6 infection.
【作者单位】：第三军医大学军事预防医学院卫生统计学教研室;第三军医大学西南医院全军感染病研究所;
【基金】：国家自然科学基金面上项目(81371849,81473068)~~
【分类号】：R512.63

【共引文献】